Source: International Congress 2017 – Many faces of asthma and allergies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Virchow (Rostock, Germany). Asthma symptoms, SABA use, and lung function before and after a moderate or severe exacerbation. 4051

Member's Comments

No comment yet.

Related content which might interest you: Severe exacerbations predict excess lung function decline in asthma Source: Eur Respir J 2007; 30: 452-456 Year: 2007 Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Problematic severe asthma Source: Eur Respir Mon 2012; 56: 22-39 Year: 2012 Blood eosinophils, exacerbations in the previous year, lung function and ICS dose predict frequent exacerbations in asthma Source: International Congress 2016 – Phenotyping asthma Year: 2016 Asthma exacerbations in relation to severe asthma Source: Eur Respir Mon 2011; 51: 120-129 Year: 2011 Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011 Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007 Mechanisms of exacerbation of respiratory symptoms in patients with COPD Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases Year: 2006 Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Physical status and dependence levels in patients with COPD exacerbation Source: International Congress 2014 – Physical activity, exercise and physiotherapy in patients with COPD Year: 2014 Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006 Evaluation and management of difficult-to-control asthma Source: Annual Congress 2007 - PG1 - Asthma: from bench to bedside Year: 2007 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014